A leading international alternative asset manager, today announced the commitment of $35 million in growth capital to Monteris Medical (“Monteris”), a MedTech company specializing in minimally invasive neurosurgical technology.
Monteris Medical develops and commercializes the NeuroBlate System, a robotically controlled laser interstitial thermal therapy (LITT) platform that uses MRI-guided laser technology to remove abnormal brain tissue. The system features robotic-controlled, precise, laser energy delivery that is used to treat brain tumors, radiation necrosis, and drug-resistant epilepsy. The NeuroBlate system is designed to provide a minimally invasive alternative to traditional open neurosurgery, with the goal of helping patients experience lower complication rates and shorter hospital stays.
“We believe Monteris is advancing innovation across the life sciences sector with technology that is expanding treatment options in neurosurgery,” said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. “We are proud to support a team that is not only pushing the boundaries of medical technology, but also delivering meaningful new treatment options for patients.”
The growth capital will help support Monteris Medical’s commercialization of the Neuroblate System and expansion of clinical research programs.
“Securing this new credit facility from Trinity Capital, alongside the support of our Series E equity investors, strengthens our ability to accelerate growth and continue delivering innovative, minimally invasive neurosurgical solutions for patients in need,” said Martin J. Emerson, President and CEO of Monteris Medical. “Trinity’s partnership reflects strong confidence in our strategy, the NeuroBlate System, and the expanding clinical impact our technology is making across leading neuroscience centers. This financing ensures we can further invest in commercial expansion, product innovation, and the teams who bring our mission to life every day.”
Read Also: American Red Cross Honors State Farm® with the 2026 Mission Leader Award
